Respiratory tract infection includes diseases such as pneumonia, influenza, bronchitis,and others which affects the respiratory organs of the body including nasal passages, throat, larynx, trachea, bronchi, or lungs. Treatment of respiratory tract infections involves use of various drugs such as antibiotics, antivirals, and pain relievers. Increasing prevalence of respiratory disorders worldwide due to pollution, changing lifestyle, and toxic work environments is fueling the growth of the respiratory tract infection treatment market.

The global respiratory tract infection treatment market is estimated to be valued at US$ 89.57 Mn in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity
Increasing adoption of combination therapies for respiratory tract infections presents a lucrative opportunity for players in the respiratory tract infection treatment market. Combination therapies use two or more drugs that work in different ways to treat respiratory infections. This helps reduce resistance developed by bacteria or viruses against single drug treatments. Players are increasingly focusing on developing fixed dose combination formulations with improved efficacy and reduced side effects. For example, in October 2021, Elpiscience announced positive phase 2 trial results for ELP-0144, a three-drug combination therapy for community-acquired bacterial pneumonia and acute exacerbation of chronic bronchitis. Thus, the demand for novel combination therapies is expected to grow significantly over the forecast period.

Porter’s Analysis

Threat of new entrants: Low capital requirements and established brands pose low threat for new entrants in this market. However, presence of stringent regulations and need for extensive R&D poses high entry barriers.

Bargaining power of buyers: Large customer base including hospitals and retail pharmacies gives them higher bargaining power over prices. Growing awareness also allows easy switching between brands.

Bargaining power of suppliers: Established suppliers including raw material producers and contract manufacturing organizations possess moderate bargaining power due to their specialized expertise and technologies.

Threat of new substitutes: Threat from alternative treatment options remains low as respiratory diseases currently have limited substitutes and treatments.

Competitive rivalry: Intense competition exists among existing players due to widespread adoption and need for continuous innovations.

SWOT Analysis

Strength: Wide brand recognition of leading pharmaceutical companies and their diversified product portfolios. Growing prevalence of respiratory diseases worldwide.

Weakness: High R&D and manufacturing costs. Drug resistance and side effects associated with few therapies. Supply chain disruptions due to pandemic.

Opportunity: Untapped growth potential in developing nations. Collaborations for developing novel drug-device combination products.

Threats: Stringent regulations for drugs approval. Patent expiries of blockbuster drugs. Reimbursement issues in some countries.

Key Takeaways

The Global Respiratory Tract Infection Treatment Market Growth is expected to witness high over the forecast period of 2023 to 2030. The market size was valued at US$ 89.57 Mn for 2024 and projected to reach over US$ 122 Mn by 2030, expanding at a CAGR of 7.1%.

Regional analysis: North America captured over 35% of the global market share in 2024 and is expected to continue dominating due to supportive reimbursement structures and availability of advanced treatment options. Asia Pacific is anticipated to exhibit fastest growth through 2030 attributed to improving access to healthcare facilities and increasing disposable incomes in developing countries such as India and China.

Key players: Key players operating in the respiratory tract infection treatment market include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd. These companies are focusing on expanding their product portfolios through acquisitions and partnerships to capitalize on future growth opportunities in emerging markets.
 

Get more insights on this topic: https://www.newsstatix.com/respiratory-tract-infection-treatment-market-size-and-share-analysis-growth-trends-and-forecasts-2023-2030/